Tresiba (Insulin Degludec) Efficacy Reports: What Real Users Actually Say

Import from '@/components/mdx'

Does Tresiba Actually Work? The Clinical Evidence First

Tresiba works. The DEVOTE trial, published in the New England Journal of Medicine in 2017 and enrolling 7,637 adults with type 2 diabetes at high cardiovascular risk, showed insulin degludec was non-inferior to insulin glargine U100 on three-point major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke). That is the headline number regulators needed.

The secondary outcome that most users actually care about: severe nocturnal hypoglycemia occurred 53% less often with degludec than with glargine in the DEVOTE trial. Fewer 2 a.m. Wake-ups, fewer seizures, fewer trips to the ER. That single finding is why so many people switch and why so many stay.

How the Mechanism Produces That Flat Line

Insulin degludec forms multi-hexamer chains after injection. Those chains slowly dissolve in subcutaneous tissue over many hours, releasing monomers steadily into circulation. The half-life is approximately 25 hours, and the glucose-lowering effect extends to 42 hours, far longer than glargine U100 (roughly 24 hours) or detemir (up to 23 hours). The result is a near-peakless action profile with a low day-to-day variability coefficient.

Low variability matters more for women than many clinicians acknowledge. A study measuring within-person variability showed degludec's day-to-day glucose variability was approximately 4-fold lower than glargine U100 in crossover comparisons. When your insulin background is more predictable, you have more room to troubleshoot the hormonal noise your cycle, your stress response, and your life add on top.

What Real HbA1c Reductions Look Like

In DEVOTE, both groups achieved similar HbA1c reductions from baseline. The trial started at a mean HbA1c of about 8.4% and ended near 7.5% in both arms after approximately two years. Real-world registry data from Denmark, where degludec has been available since 2013, echo those numbers: most people with type 2 diabetes on degludec land in the 7.0 to 7.5% range after 12 months of optimized therapy.

What Real Users Say: Reddit, Drugs.com, and PatientsLikeMe

This section is honest about what it is. Online reviews represent a self-selected group: people who felt strongly enough to write something. That is selection bias. Sample sizes are small compared to a clinical trial. Still, patterns that appear across thousands of posts and reviews carry real signal.

Reddit: r/diabetes, r/diabetes_t1, r/diabetes_t2

Reddit discussions about Tresiba cluster around three themes: stability, flexibility in injection timing, and the learning curve on dosing.

A frequently upvoted post in r/diabetes_t1 describes the experience this way: "Switched from Lantus after 12 years. First two weeks were bumpy while I dialed in the dose. Then it was like someone turned down the noise. My CGM trace overnight went from a roller coaster to basically a straight line." This matches the pharmacokinetic story precisely.

The flexibility theme comes up repeatedly. Because the half-life is so long, missing a dose by several hours does not cause the sharp glucose spike that a missed Lantus dose might. Multiple threads in r/diabetes confirm that the prescribing information allows dose timing flexibility of up to 8 hours when a dose is missed, which users describe as reducing anxiety around travel, shift work, and irregular schedules.

The dosing learning curve is a consistent frustration. Several users note that because the half-life is so long, a dose adjustment takes 3 to 4 days to fully show its effect. "Don't panic and stack," is a warning that appears in multiple threads. Experienced users recommend waiting at least 3 days before increasing a basal dose.

Drugs.com: 300+ Reviews, 8.1 Average Rating

The Drugs.com aggregate paints a favorable picture. Common themes in 5-star reviews include fewer overnight lows, better morning glucose, and reduced glucose variability. Common themes in 1-star reviews include insurance denials (forcing switches back to glargine), injection site issues, and frustration during the initial titration period.

One reviewer with type 1 diabetes and diagnosed PCOS wrote: "My endo switched me to Tresiba when my cycles were making my Lantus dose unpredictable. It hasn't solved the hormonal swings, but the baseline is steadier so at least I can tell what's the cycle and what's my basal dose."

That comment reflects something clinically real and under-discussed.

PatientsLikeMe

PatientsLikeMe data skews toward people with type 1 diabetes and a longer duration of disease. Ratings there mirror Drugs.com: high satisfaction for glucose stability, lower satisfaction during transitions and insurance-related formulary switches.

Tresiba and the Female Body: What the Clinical Evidence Misses

Most Tresiba trial data comes from mixed-sex populations with limited sex-stratified reporting. The DEVOTE trial enrolled approximately 37% women. That is better than many older cardiovascular trials but still means the primary efficacy and safety data is majority male. What follows is an evidence-based framework for thinking about Tresiba across female life stages, drawing on physiology and smaller sex-specific studies where they exist. Be aware this is partly extrapolation.

The Menstrual Cycle and Basal Insulin Needs

Estrogen and progesterone both affect insulin sensitivity, but in opposite directions and at different cycle phases. In the follicular phase, rising estrogen tends to improve insulin sensitivity modestly. In the luteal phase, rising progesterone reduces insulin sensitivity, often raising fasting glucose by 10 to 30 mg/dL in women with type 1 diabetes.

A 2013 study in Diabetes Care found that women with type 1 diabetes required, on average, 12% more total daily insulin during the luteal phase compared to the follicular phase. That fluctuation is real and not solved by any basal insulin. What Tresiba offers is a more stable floor. You are still adjusting for hormonal variation, but you are adjusting on top of a more predictable base.

Practical implication: if you track your cycle, consider logging your basal dose alongside your CGM data. Patterns across 2 to 3 cycles can reveal whether your luteal-phase dose needs a planned bump.

PCOS and Insulin Resistance

PCOS affects approximately 8 to 13% of women of reproductive age and carries substantial insulin resistance even without a diabetes diagnosis. For women with PCOS who develop type 2 diabetes, the underlying insulin resistance is often more pronounced than in women without PCOS.

Tresiba does not treat PCOS-related hyperandrogenism or anovulation directly. But adequate glycemic control does reduce the hyperinsulinemia that worsens androgen excess. Metformin is still the first-line agent for most women with PCOS and type 2 diabetes, but when basal insulin is needed, degludec's low variability profile may help separate what is glycemic from what is hormonal when you are trying to adjust.

Perimenopause and Post-Menopause

The estrogen decline of perimenopause typically worsens insulin resistance, raises fasting glucose, and shifts fat distribution toward visceral adiposity. Women with type 1 diabetes who enter perimenopause frequently report that their previously stable insulin regimens stop working as expected.

No large trial has specifically examined insulin degludec in perimenopausal or postmenopausal women with type 1 diabetes. What exists is observational: case series and registry data suggesting that the lower variability of degludec helps isolate perimenopausal hormonal noise from true basal dose inadequacy. If you are in perimenopause and your overnight glucose pattern has recently changed, that conversation belongs with both your endocrinologist and a menopause-informed clinician who can assess whether menopausal hormone therapy might reduce insulin requirements alongside optimizing your basal dose.

Pregnancy and Lactation Safety: What You Need to Know

Tresiba is not contraindicated in pregnancy. It does not carry a teratogenic warning. "not contraindicated" is not the same as "extensively studied in pregnancy," and this distinction matters.

Pregnancy Data

Insulin degludec was classified FDA Pregnancy Category B based on animal reproductive studies showing no harm to the fetus at doses higher than human therapeutic doses. Human data in pregnancy is limited. The most relevant evidence comes from the EXPECT trial, a randomized controlled trial comparing degludec with detemir in pregnant women with type 1 diabetes. Published in Lancet Diabetes & Endocrinology in 2019, EXPECT enrolled 223 pregnant women and found degludec was non-inferior to detemir on HbA1c at 36 weeks, with a similar rate of severe hypoglycemia and no increase in adverse fetal outcomes.

Both the American Diabetes Association Standards of Care and ACOG acknowledge that insulin is the preferred pharmacologic agent for diabetes management in pregnancy. Degludec may be used when it is the patient's established regimen and switching would risk destabilizing glucose control. Initiating degludec de novo in pregnancy, rather than continuing an established regimen, is less common and should involve shared decision-making with your maternal-fetal medicine team.

Insulin requirements increase substantially across trimesters, particularly in the second and third trimester, often requiring dose increases of 50 to 100% above pre-pregnancy baseline. Frequent dose adjustments are the rule, not the exception. Use of a continuous glucose monitor (CGM) during pregnancy significantly improves outcomes and is now standard of care.

Postpartum Insulin Requirements

Postpartum insulin requirements drop sharply, often within hours of delivery. Women with type 1 diabetes frequently need to reduce basal insulin by 30 to 50% immediately after birth to avoid severe hypoglycemia. Because degludec's action extends up to 42 hours, a dose given late in labor continues contributing to glucose lowering well into the postpartum period. Your care team should anticipate this and have a specific postpartum dose plan in place before delivery.

Lactation

Insulin does not transfer meaningfully into breast milk in bioavailable form. Any insulin that does pass into milk is degraded in the infant's gastrointestinal tract and not absorbed systemically. Breastfeeding itself affects insulin sensitivity, often lowering glucose and reducing insulin requirements further. Monitor glucose closely during nursing, particularly during and after feeds.

Contraception

Tresiba is not a teratogen requiring mandatory contraception. However, unplanned pregnancy in women with diabetes carries real risk: pre-conception glucose control is one of the strongest predictors of neural tube defect risk and first-trimester miscarriage. If pregnancy is not planned, reliable contraception alongside glycemic management is sound clinical practice regardless of which insulin you use.

Who Tresiba Is Right For, and Who Should Think Twice

Life Stages and Conditions Where Tresiba Often Fits Well

• Reproductive years with type 1 diabetes and a variable cycle. The flat action profile gives a more stable glycemic floor to work from when your luteal-phase insulin resistance spikes.
• Women with type 2 diabetes and PCOS who need basal insulin after metformin and lifestyle modification have not achieved target HbA1c.
• Shift workers or women with irregular schedules. The 8-hour injection timing flexibility is a practical advantage.
• Women with a history of nocturnal hypoglycemia on glargine or detemir. The DEVOTE data showing 53% fewer severe nocturnal events is relevant here.
• Perimenopausal women with type 1 diabetes whose previously stable dose has become unpredictable. The lower variability may help separate hormonal from dose-related glucose shifts, though evidence is observational.

Situations That Deserve Extra Conversation With Your Provider

• Early pregnancy or planning pregnancy. Not contraindicated, but requires close monitoring and frequent dose adjustment. If you are already on detemir and well-controlled, your team may prefer to continue it given slightly more pregnancy-specific data.
• Women with severe insulin resistance (common in type 2 diabetes with BMI above 35 or significant PCOS). Very high basal doses of degludec may be needed; the U200 concentration formulation exists for this reason.
• Formulary or cost constraints. Tresiba remains more expensive than biosimilar glargine in many markets. An honest cost-benefit conversation matters.
• Recent history of DKA or significant dose instability. The 3 to 4 day lag before dose changes take full effect can be frustrating and risky in someone whose needs are changing rapidly.

How to Read Online Reviews Without Being Misled

User reviews of Tresiba, whether on Reddit, Drugs.com, or PatientsLikeMe, carry a structural limitation: people who switch and find the drug unremarkable are unlikely to post. People who switch and experience dramatic improvement, or dramatic failure, write detailed accounts. This means online sentiment overrepresents both extremes.

A useful rule when reading any insulin review thread: note whether the poster also changed their bolus insulin, CGM system, or injection site practice at the same time. Changes in concurrent therapy confound self-reports constantly.

The most credible user reports name their starting dose, their titration approach, their CGM system, and the specific outcomes they were tracking, HbA1c, nocturnal lows, time in range, standard deviation on their CGM. Those details allow you to compare your situation to theirs. A post that says "Tresiba ruined my life" with no other context is noise. A post that says "Started at 12 units, titrated by 2 units every 3 days, my nocturnal TIR went from 62% to 81% over 8 weeks" is signal.

Practical Dosing Notes for Women

Starting doses are generally 10 units once daily, or 10% of the total daily insulin dose if converting from another basal insulin for type 2 diabetes. For type 1 diabetes, the conversion is typically unit-to-unit from the previous basal dose. Titrate by 2 units every 3 days to reach a fasting glucose target.

The injection can be given at any time of day, but consistency matters more early in therapy. Once you are at a stable dose, shifting the timing by a few hours does not destabilize control. Rotate injection sites among abdomen, thigh, and upper arm to reduce lipohypertrophy.

If your fasting glucose is running high in the luteal phase of your cycle each month, discuss with your endocrinologist whether a planned, modest luteal-phase basal increase (rather than reactive dose changes) is appropriate for your situation.